IMM vs. REDX, ETX, SBTX, COS, C4XD, DDDD, TRX, FUM, OKYO, and SAR
Should you be buying ImmuPharma stock or one of its competitors? The main competitors of ImmuPharma include Redx Pharma (REDX), e-therapeutics (ETX), SkinBioTherapeutics (SBTX), Collagen Solutions plc (COS.L) (COS), C4X Discovery (C4XD), 4D pharma (DDDD), Tissue Regenix Group (TRX), Futura Medical (FUM), OKYO Pharma (OKYO), and Sareum (SAR). These companies are all part of the "biotechnology" industry.
ImmuPharma vs.
ImmuPharma (LON:IMM) and Redx Pharma (LON:REDX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their media sentiment, profitability, valuation, dividends, earnings, analyst recommendations, institutional ownership, risk and community ranking.
ImmuPharma has a net margin of 3,519.56% compared to Redx Pharma's net margin of 0.00%. ImmuPharma's return on equity of -131.41% beat Redx Pharma's return on equity.
ImmuPharma has a beta of 1.53, meaning that its share price is 53% more volatile than the S&P 500. Comparatively, Redx Pharma has a beta of -0.53, meaning that its share price is 153% less volatile than the S&P 500.
ImmuPharma received 113 more outperform votes than Redx Pharma when rated by MarketBeat users. Likewise, 76.44% of users gave ImmuPharma an outperform vote while only 73.56% of users gave Redx Pharma an outperform vote.
In the previous week, ImmuPharma had 1 more articles in the media than Redx Pharma. MarketBeat recorded 1 mentions for ImmuPharma and 0 mentions for Redx Pharma. ImmuPharma's average media sentiment score of 0.32 beat Redx Pharma's score of 0.00 indicating that ImmuPharma is being referred to more favorably in the media.
17.4% of ImmuPharma shares are owned by institutional investors. Comparatively, 72.7% of Redx Pharma shares are owned by institutional investors. 48.3% of ImmuPharma shares are owned by insiders. Comparatively, 18.4% of Redx Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
ImmuPharma has higher earnings, but lower revenue than Redx Pharma. ImmuPharma is trading at a lower price-to-earnings ratio than Redx Pharma, indicating that it is currently the more affordable of the two stocks.
Summary
ImmuPharma beats Redx Pharma on 11 of the 14 factors compared between the two stocks.
Get ImmuPharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for IMM and its competitors with MarketBeat's FREE daily newsletter.
Media Sentiment Over Time
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ImmuPharma Competitors List
Related Companies and Tools
This page (LON:IMM) was last updated on 5/22/2025 by MarketBeat.com Staff
Buy IMM Stock Free IMM Stock Alerts